A randomized, double‐blind, placebo‐controlled trial of TAK‐242 showed a trend towards a reduced 28‐day mortality in patients with both septic shock and respiratory failure in the treatment group, but the result was not significant (Rice et al . 2010 ).
← all excerpts
Physiological aspects of Toll-like receptor 4 activation in sepsis-induced acute kidney injury.
1
—
—